TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18447219

Group type: EXPERIMENTAL
Intervention: Drug-separated moxibustion at Shenque (CV 8)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Oral administration of Smecta (Control)
Number of subjects: 136
Study: 17388006

Group type: EXPERIMENTAL
Intervention: 10 mg atorvastatin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 10 mg simvastatin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 200 mg fenofibrate
Number of subjects: 100
Study: 12962953

Group type: COMPARATOR
Intervention: Prophylactic cerclage
Number of subjects: 2175

Group type: COMPARATOR
Intervention: Cervical cerclage
Number of subjects: 2175
Study: 10774248

Group type: EXPERIMENTAL
Intervention: Lenograstim 2 micrograms/kg/day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lenograstim 5 micrograms/kg/day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lenograstim 10 micrograms/kg/day
Number of subjects: 18
Study: 8897357

Group type: EXPERIMENTAL
Intervention: Benzathine penicillin (PCN) administered at a dose of 1,200,000 u, intramuscularly at 3-week intervals for at least one year.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Benzathine penicillin (PCN)
Number of subjects: 45
Study: 1677774

Group type: EXPERIMENTAL
Intervention: Alpidem (225 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lorazepam (4.5 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 6647190

Group type: EXPERIMENTAL
Intervention: Metronidazole (500 mg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Cefoxitin (1 g)
Number of subjects: 96
Study: 12206065

Group type: EXPERIMENTAL
Intervention: Needle Exchange Condition (access to NS via an experimental needle exchange program)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Pharmacy Sales Condition (access to NS via legal sales of nonprescription NS)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Both conditions (Needle Exchange and Pharmacy Sales)
Number of subjects: 176
Study: 30413154

Group type: EXPERIMENTAL
Intervention: Precizon toric IOL
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tecnis toric IOL
Number of subjects: 40
Study: 27676664

Group type: EXPERIMENTAL
Intervention: Pulsed dose radiofrequency followed by continuous thermal radiofrequency ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thermal radiofrequency ablation alone
Number of subjects: 0
Study: 24886232

Group type: EXPERIMENTAL
Intervention: Palliative care
Number of subjects: 1681

Group type: COMPARATOR
Intervention: Life-prolonging/curative treatment
Number of subjects: 1681
Study: 22245134

Group type: EXPERIMENTAL
Intervention: Heavier container
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lighter container
Number of subjects: 0
Study: 20715523

Group type: EXPERIMENTAL
Intervention: Pulsation group
Number of subjects: 100

Group type: COMPARATOR
Intervention: US group
Number of subjects: 100
Study: 18554712

Group type: EXPERIMENTAL
Intervention: LT-patch (37.5 mug of heat-labile toxin from E. coli)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 15922193

Group type: EXPERIMENTAL
Intervention: AI/AN race
Number of subjects: 2215

Group type: COMPARATOR
Intervention: Caucasian race
Number of subjects: 2215
Study: 12390335

Group type: EXPERIMENTAL
Intervention: 0.5 mg melatonin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 5.0 mg melatonin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10439603

Group type: EXPERIMENTAL
Intervention: Problem-based small-group learning (PBSGL) intervention via the Internet for 11 family physicians over two months with facilitator and geriatric psychiatrists.
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group receiving similar educational resources via the Internet without small-group interaction for 12 family physicians.
Number of subjects: 23
Study: 7794984

Group type: EXPERIMENTAL
Intervention: Wrist orthoses
Number of subjects: 69

Group type: COMPARATOR
Intervention: No wrist orthoses
Number of subjects: 69
Study: 2146370

Group type: EXPERIMENTAL
Intervention: resection and continuous hepatic artery infusion (CHAI) of fluorodeoxyuridine (FUdR) in arm A2
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: CHAI only in arm B2
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: systemic fluorouracil followed by CHAI in arm C2
Number of subjects: 91

Group type: COMPARATOR
Intervention: resection only in arm A1
Number of subjects: 91
Study: 1032070

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.15 mg and 0.3 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.6 mg and 1.2 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine (5 mg and 10 mg)
Number of subjects: 0
Study: 31053885

Group type: EXPERIMENTAL
Intervention: MIS posterior approach
Number of subjects: 64

Group type: COMPARATOR
Intervention: mDL approach
Number of subjects: 64
Study: 26418205

Group type: EXPERIMENTAL
Intervention: 2% sevoflurane during CPB
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control (oxygen-air mixture)
Number of subjects: 103
Study: 24722496

Group type: EXPERIMENTAL
Intervention: INT131 0.5 mg
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: INT131 1 mg
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: INT131 2 mg
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg
Number of subjects: 367

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 367
Study: 23755953

Group type: EXPERIMENTAL
Intervention: Routine semen analyses, sperm DNA, and chromatin assessments
Number of subjects: 129
Study: 20838058

Group type: EXPERIMENTAL
Intervention: Capecitabine (CAP)
Number of subjects: 71

Group type: COMPARATOR
Intervention: CEF (cyclophosphamide/epirubicin/5-fluorouracil)
Number of subjects: 71
Study: 18982032

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1 drop immediately after surgery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1 drop every 12 hours starting immediately after surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: No ocular hypotensive medication (control group)
Number of subjects: 60
Study: 15974850

Group type: EXPERIMENTAL
Intervention: Root planing and polishing
Number of subjects: 24

Group type: COMPARATOR
Intervention: Polishing alone
Number of subjects: 24
Study: 12832740

Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study: 10804484

Group type: EXPERIMENTAL
Intervention: Exercise group (30 minutes of exercise at RPE level 13, three times a week for 10 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Comparison of pre-post change in DBP between groups
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exercise treatment
Number of subjects: 16
Study: 1779870

Group type: EXPERIMENTAL
Intervention: Late umbilical cord clamping
Number of subjects: 554

Group type: COMPARATOR
Intervention: Early umbilical cord clamping
Number of subjects: 554
Study: 6320580

Group type: EXPERIMENTAL
Intervention: Pivampicillin-pivmecillinam (PAPM)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Trimethoprim-sulphamethoxazole (TMPS)
Number of subjects: 82
Study: 28936692

Group type: EXPERIMENTAL
Intervention: Therapeutic relationship in music therapy
Number of subjects: 48
Study: 29575669

Group type: EXPERIMENTAL
Intervention: prepCheck-supported self-assessment (n=24)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional faculty supervision (n=23)
Number of subjects: 47
Study: 26525206

Group type: EXPERIMENTAL
Intervention: Single-layer suture anastomosis (SLA)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Double-layer suture anastomosis (DLA)
Number of subjects: 252
Study: 26298934

Group type: EXPERIMENTAL
Intervention: Intense bladder control education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 22306844

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate and ibuprofen (combined therapy)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 71
Study: 20839311

Group type: EXPERIMENTAL
Intervention: Imagery rehearsal
Number of subjects: 124

Group type: COMPARATOR
Intervention: Credible active comparison condition
Number of subjects: 124
Study: 17599766

Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg daily)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Aspirin (observational study)
Number of subjects: 98

Group type: COMPARATOR
Intervention: No aspirin (observational study)
Number of subjects: 98
Study: 16053839

Group type: EXPERIMENTAL
Intervention: Wire fixation
Number of subjects: 3

Group type: COMPARATOR
Intervention: Rigid internal fixation (RIF)
Number of subjects: 3
Study: 12475666

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 190
Study: 9536505

Group type: EXPERIMENTAL
Intervention: Amlodipine (AML) 5 mg/day, increasing to 10 mg/day after 2 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Amlodipine (AML) 10 mg/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Amlodipine (AML) 5 mg/day and 10 mg/day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 7628027

Group type: EXPERIMENTAL
Intervention: Butorphanol (30 micrograms.kg‐1)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Morphine (150 micrograms.kg‐1)
Number of subjects: 156
Study: 2021198

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) infusion
Number of subjects: 39
Study: 6124440

Group type: EXPERIMENTAL
Intervention: KWD 2131 (250 micrograms)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Terbutaline (25 micrograms)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: KWD 2131 (100 micrograms)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Terbutaline (10 micrograms)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: KWD 2131 (25 micrograms)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Terbutaline (2.5 micrograms)
Number of subjects: 10
Study: 31694810

Group type: EXPERIMENTAL
Intervention: Authors' full International Committee of Medical Journal Editors format conflict of interest disclosures
Number of subjects: 838

Group type: COMPARATOR
Intervention: No authors' conflict of interest disclosures
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Counterfactual scores
Number of subjects: 838
Study: 28353611

Group type: EXPERIMENTAL
Intervention: Intra-articular lumbar facet joint pulsed radiofrequency (PRF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intra-articular lumbar facet joint corticosteroid injection (ICI)
Number of subjects: 60
Study: 29797981

Group type: COMPARATOR
Intervention: Systemic steroid therapy
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Steroid combined with dehydrant therapy
Number of subjects: 82
Study: 25268438

Group type: EXPERIMENTAL
Intervention: Needle acupuncture
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Number of subjects: 282

Group type: COMPARATOR
Intervention: Sham laser acupuncture
Number of subjects: 282

Group type: COMPARATOR
Intervention: Control (no acupuncture)
Number of subjects: 282
Study: 22424787

Group type: EXPERIMENTAL
Intervention: Oxytocin (24IU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxytocin (24IU) administered in the second session
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (unknown to participants and experimenter)
Number of subjects: 0
Study: 19367322

Group type: EXPERIMENTAL
Intervention: Risk-reducing salpingo-oophorectomy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Screening (Control)
Number of subjects: 300
Study: 17617812

Group type: EXPERIMENTAL
Intervention: Fungi on walls of the house
Number of subjects: 1760

Group type: EXPERIMENTAL
Intervention: Frequent use of microwave oven at home
Number of subjects: 1760
Study: 15042116

Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Atenolol-based treatment
Number of subjects: 847
Study: 11782325

Group type: EXPERIMENTAL
Intervention: Continuous infusion of racemic methadone (initial doses of 3 to 6 mg followed by 6 to 12 mg over 24 hr)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Bolus administration of racemic methadone (repeated boluses of 3 to 6 mg every eight hours)
Number of subjects: 90
Study: 9633672

Group type: EXPERIMENTAL
Intervention: 100-g TFD (tryptophan-free amino acid drink)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 25-g TFD (control drink)
Number of subjects: 10
Study: 7866680

Group type: EXPERIMENTAL
Intervention: Insulin hypoglycaemia (IH) test
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dexamethasone suppression test (DST)
Number of subjects: 16
Study: 1967919

Group type: EXPERIMENTAL
Intervention: Loratadine, 10 mg OD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terfenadine, 60 mg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7350203

Group type: EXPERIMENTAL
Intervention: Intranasal flunisolide 200 micrograms/day
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Intranasal flunisolide
Number of subjects: 56
Study: 31776620

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 305

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 305
Study: 31870427

Group type: EXPERIMENTAL
Intervention: Nonplacement of a cervical drainage tube
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placement of a cervical drainage tube
Number of subjects: 110
Study: 27937096

Group type: EXPERIMENTAL
Intervention: Onartuzumab plus erlotinib
Number of subjects: 499

Group type: COMPARATOR
Intervention: Placebo plus erlotinib
Number of subjects: 499
Study: 26664397

Group type: EXPERIMENTAL
Intervention: Gabapentin 100 mg/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg/day
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 90
Study: 23680127

Group type: EXPERIMENTAL
Intervention: ABThera Open Abdomen Negative Pressure Therapy System
Number of subjects: 0

Group type: COMPARATOR
Intervention: Barker's vacuum pack
Number of subjects: 0
Study: 21827934

Group type: EXPERIMENTAL
Intervention: Spirituality teaching program (8-week intervention using audio CDs for home-based use)
Number of subjects: 15
Study: 17597132

Group type: EXPERIMENTAL
Intervention: Vipassana meditation course
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 15619332

Group type: EXPERIMENTAL
Intervention: Radionuclide studies of upper GI function
Number of subjects: 32

Group type: COMPARATOR
Intervention: Questionnaire on upper GI symptoms
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oesophageal clearance studies
Number of subjects: 32
Study: 11479469

Group type: EXPERIMENTAL
Intervention: DDD mode with the rate‐smoothing algorithm (RSA) on
Number of subjects: 14

Group type: COMPARATOR
Intervention: OOO mode
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Rate-smoothing mode
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: RSA ON arm
Number of subjects: 14
Study: 9493805

Group type: EXPERIMENTAL
Intervention: MEDI‐493 (palivizumab) 3 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MEDI‐493 (palivizumab) 10 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MEDI‐493 (palivizumab) 15 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 0
Study: 7520676

Group type: EXPERIMENTAL
Intervention: Filgrastim (12 micrograms/kg of body weight per day)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study: 2528257

Group type: EXPERIMENTAL
Intervention: 20% azelaic acid cream
Number of subjects: 381

Group type: COMPARATOR
Intervention: 0.05% tretinoin cream
Number of subjects: 381

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 381
Study: 60566

Group type: EXPERIMENTAL
Intervention: Timolol (10 mg thrice daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Timolol plus Hydrochlorothiazide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (no treatment)
Number of subjects: 20
Study: 31749051

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide (FAc) implant
Number of subjects: 49

Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 49
Study: 31422789

Group type: EXPERIMENTAL
Intervention: Vertebral angioplasty/stenting plus best medical treatment (BMT)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Best medical treatment (BMT) alone
Number of subjects: 182
Study: 26644166

Group type: EXPERIMENTAL
Intervention: Synbiotics during chemotherapy (n=30)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (n=31)
Number of subjects: 61
Study: 25733548

Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard care hydrocolloid dressing
Number of subjects: 70
Study: 23800627

Group type: EXPERIMENTAL
Intervention: Higher protein formula (HP: 2.05 and 3.2 g/100 mL)
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Lower protein formula (LP: 1.25 and 1.6 g/100 mL)
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Breastfed infants (BF)
Number of subjects: 1090
Study: 21856515

Group type: EXPERIMENTAL
Intervention: Culturally sensitive mass media intervention delivered via television and radio for more than 3 years.
Number of subjects: 1346

Group type: COMPARATOR
Intervention: Control group (nonmedia cities: Providence, RI; Columbia, SC).
Number of subjects: 1346
Study: 19875318

Group type: EXPERIMENTAL
Intervention: PLGA-beta-TCP composite
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hemostatic gauze
Number of subjects: 30

Group type: COMPARATOR
Intervention: Buccal flap technique
Number of subjects: 30
Study: 16715577

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 481

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 481
Study: 14687137

Group type: EXPERIMENTAL
Intervention: Computer-based colonoscopy simulation (CBCS) training for 6 hours
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (traditionally trained fellows)
Number of subjects: 8
Study: 11246738

Group type: EXPERIMENTAL
Intervention: Various interventions in phase 3 trials for urinary bladder cancer therapy
Number of subjects: 1000
Study: 9223197

Group type: EXPERIMENTAL
Intervention: Tetracaine 15 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bupivacaine 15 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lidocaine 100 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (CPT before anesthesia)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CPT after spinal anesthesia
Number of subjects: 12
Study: 7954529

Group type: EXPERIMENTAL
Intervention: Intrapleural OK-432 injection
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control (no intrapleural OK-432 injection)
Number of subjects: 93
Study: 2880885

Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Terfenadine 180 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31943168

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (subgroup analysis)
Number of subjects: 42
Study: 29452584

Group type: EXPERIMENTAL
Intervention: P1000/Ca500 (1000 mg/d phosphorus and 500 mg/d calcium)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: P1000/Ca1000 (1000 mg/d phosphorus and 1000 mg/d calcium)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (sherbet powder)
Number of subjects: 62
Study: 27151156

Group type: EXPERIMENTAL
Intervention: VERSE therapy - a prescribed and structured aphasia therapy program, 20 additional sessions (45-60 min, provided daily) before day 50 post stroke.
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: UC-plus usual ward-based therapy, 20 additional sessions (45-60 min, provided daily) before day 50 post stroke.
Number of subjects: 246

Group type: COMPARATOR
Intervention: UC-no additional therapy.
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Discourse measures, Stroke and Aphasia Quality of Life Scale-39, and Aphasia Depression Rating Scale.
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Economic evaluation of incremental cost-effectiveness ratios.
Number of subjects: 246
Study: 26905548

Group type: EXPERIMENTAL
Intervention: Ondansetron (100 microgram/kg IV)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Granisetron (40 microgram/kg IV)
Number of subjects: 90
Study: 23532888

Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg b.i.d.) plus modified FOLFOX6 (mFOLFOX6)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo plus modified FOLFOX6 (mFOLFOX6)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Sorafenib plus mFOLFOX6
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo plus mFOLFOX6
Number of subjects: 198
Study: 20648201

Group type: EXPERIMENTAL
Intervention: Pulse width programming (50-1000 microseconds)
Number of subjects: 19
Study: 18826858

Group type: EXPERIMENTAL
Intervention: Platelet activation parameters (CD62P, CD63, PAC-1, CD42b, CD41)
Number of subjects: 93
Study: 17121038

Group type: EXPERIMENTAL
Intervention: Xinshuai Mistura (XM)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Wuling Pulvis (WP)
Number of subjects: 59
Study: 12813383

Group type: EXPERIMENTAL
Intervention: Leukocyte depletion group (n=40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (n=40)
Number of subjects: 80
Study: 10867764

Group type: EXPERIMENTAL
Intervention: Transmyocardial revascularization (TMR) using holmium:yttrium‐aluminium‐garnet (YAG) and carbon dioxide lasers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transmyocardial revascularization (TMR) as an adjunct to coronary artery bypass grafting (CABG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 0
Study: 8795804

Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg p.o. taken at 20.00 hours for 1 week
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo taken at 20.00 hours for 1 week
Number of subjects: 15
Study: 1319975

Group type: EXPERIMENTAL
Intervention: 60 mg fluoxetine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30